Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to CSHL, Alnylam, Merck, and More


Title: Methods and Compositions for RNA Interference

Patent Number: 8,202,846

Filed: Nov. 23, 2004

Lead Inventor: Greg Hannon, Cold Spring Harbor Laboratory

The invention, the patent's abstract states, “provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double stranded RNA, such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited.”

Title: Methods and Compositions for Inhibition of Stat5 in Prostate Cancer

Patent Number: 8,202,849

Filed: Aug. 26, 2009

Inventor: Marja Nevalainen, Georgetown University

The invention relates to “compositions and methods for the treatment of prostate cancer,” the patent's abstract states. “In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells.”

Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Patent Number: 8,202,979

Filed: May 23, 2003

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention relates to “methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target-validation, and genomic-discovery applications,” the patent's abstract states. “Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules ... capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”

Title: Method and Medicament for Inhibiting the Expression of a Given Gene

Patent Number: 8,202,980

Filed: July 2, 2003

Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

The invention, the patent's abstract states, “provides methods and compositions for inhibiting gene expression using double-stranded RNA molecules that are between 15 and 21 nucleotides in length and are complementary to a target gene sequence.”

Title: Compositions and Methods for the Systemic Treatment of Arthritis

Application Number: 20120148498

Filed: Feb. 28, 2012

Lead Inventor: Jacques Banchereau, Baylor Research Institute

The invention, the patent application's abstract states, “includes compositions and methods for treating arthritic joints found in patients with auto-inflammation … by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bio-availability of interleukin-1-beta.”

Title: Detection of Small Nucleic Acids

Application Number: 20120149018

Filed: Feb. 7, 2012

Lead Inventor: James Dahlberg, Third Wave Technologies (Hologic)

The invention “relates to compositions and methods for the detection and characterization of interfering RNAs such as microRNAs ... small interfering RNAs, and other short nucleic acid molecules,” according to the patent application's abstract. “More particularly, the ... invention relates to improved methods for the detection and quantitation of interfering RNA expression … [and] further provides for the detection of variants and types of miRNAs and siRNAs.”

Title: Methods and Compositions for Seamless Cloning of Nucleic Acid Molecules

Application Number: 20120149069

Filed: Feb. 21, 2012

Lead Inventor: Jonathan Chesnut, Life Technologies

The invention, the patent application's abstract states, “relates to cloning or subcloning one or more nucleic acid molecules comprising one or more type IIs restriction enzyme recognition sites. The … invention also embodies cloning [these] nucleic acid molecules using recombinational cloning methods such as those employing recombination sites and recombination proteins. The ... invention also relates to nucleic acid molecules, as well as proteins, expressed from host cells produced using the methods of the present invention.”

Title: Methods of Predicting the Risk of Recurrence of Cancer

Application Number: 20120149586

Filed: Aug. 14, 2009

Inventor: Glen Weiss, Translational Genomics Research Institute

The invention comprises “methods of predicting the risk of recurrence of cancer on the basis of the expression of microRNA of the miR-520 family,” according to the patent application's abstract.

Title: Nucleic Acid Molecules and Uses Thereof

Application Number: 20120149761

Filed: Aug. 27, 2010

Inventor: Steven Quay, Atossa Genetics

The invention, the patent application's abstract states, comprises “formulations of double-stranded RNA molecules and Krebs cycle analogs that [are useful in] improving ribonuclease stability, reducing off-target effects of a double-stranded siRNA molecule, or … reducing interferon responsiveness of a double-stranded siRNA molecule using such dsRNA. Also disclosed are methods of treating a primary tumor or a metastasis by contacting circulating tumor cells, a primary tumor, or a metastasis with a described formulation.”

Title: Novel Cationic Lipids with Various Head Groups for Oligonucleotide Delivery

Application Number: 20120149894

Filed: Aug. 18, 2010

Lead Inventor: Mark Cameron, Merck

The invention comprises “novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with siRNA, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo,” according to the patent application's abstract.

Title: Microneedle Arrays for Active Agent Delivery

Application Number: 20120150023

Filed: June 9, 2011

Lead Inventor: Roger Kaspar, TransDerm

The invention comprises “microneedle arrays and related systems and methods … particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines,” the patent application's abstract states. “Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided.”

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.